Weekender: A serial biotech entrepreneur launches his next startup with high-dollar backing

Signup | Forward Weekender Dec.​ 11,​ 2021 | A roundup of this week's most read stories

BROUGHT TO YOU BY — Definitive Healthcare White Paper: Smarter commercial decisions for biopharma pipeline assets Learn how healthcare commercial intelligence can help you optimize your commercialization strategy and earn the proper value for your drug or treatment when you go to market. Get the White Paper.   A serial biotech entrepreneur launches his next startup with high-dollar backing Founded and led by Gary Glick, Odyssey Therapeutics has raised $218 million in Series A funding for its cancer and inflammatory disease drug research. AbbVie's blockbuster weighed down by safety concerns for a similar Pfizer drug Like Pfizer's Xeljanz, the label for AbbVie's Rinvoq has been updated to warn about risks of death and major cardiovascular events like stroke. AstraZeneca wagers $200M on Ionis' next chance at a rare disease drug The alliance follows AstraZeneca's buyout of Alexion last year and puts the British drugmaker in competition with Alnylam, Bridgebio and several others. Sponsored Content by Elemental Machines The State of LabOps In this inaugural report, Elemental Machines presents timely insights regarding the rapidly evolving future of LabOps, strategies to optimize lab operations and tools that warrant a place at the strategic table. Download the eBook. Biohaven to seek FDA approval for second migraine drug after study success The biotech's drug, called zavegepant, is delivered intranasally and could offer a similar convenience advantage as its first, the fast-selling Nurtec ODT. A high-profile gene therapy biotech takes aim at Huntington's Passage Bio and the University of Pennsylvania's Gene Therapy Program said they have begun preclinical research aimed at simultaneously developing multiple approaches to treating Huntington's. Featured Resources Sponsored Content by Vileda Professional® Are you truly eliminating contamination risk in your facility? [Video] CE Duo® double-sided, microfiber cleanroom mop system to reduce contamination [Web Page] Learn more on how CE Duo® can help minimize the risk! [Catalog] Innovative cleaning systems that outperform the competition! From Our Library Playbook Vaccinating the Globe: Choosing the Right CDMO Partner PCI Webinar - on demand Getting Your Data Aggregation Contract Right in Pharma IQVIA Webinar - on demand Biosimilars and Real-World Evidence: A Path to Regulatory Efficiency and Adoption Cardinal Health Playbook Accelerating Biotech Discovery With High-Dimensional Biology and Bioinformatics BD Biosciences Playbook Critical & Time-Sensitive Cold Chain Shipments Best Practices Tive View all resources Best of What We're Reading Nature RNAi drugs at “a remarkable period of a renaissance” FierceBiotech Novartis poaches Roche's neuro and rare disease R&D lead Associated Press $56K Alzheimer’s drug avoiding Biden’s cost curbs, for now Reuters Novartis CEO says Sandoz attracting interest - paper Bloomberg The Hunt for a Single Shot to Defeat Omicron and All Coronaviruses The Wall Street Journal The Elizabeth Holmes Trial: The Defense Rests Its Case Suggest a story we should read Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Daily Dive with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Daily Dive. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc. 1255​ 23rd Street NW, Suite 550, Washington,​ DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip